Fluticasone-salmeterol and budesonide-formoterol
(Redirected from Budesonide-Formoterol)
| Drug monograph · NCLEX study reference | |
| Trade names | Advair, Symbicort |
|---|---|
| Therapeutic class | Asthma and COPD controller |
| Pharmacologic class | Inhaled corticosteroid plus long-acting beta agonist combination |
| Onset / peak / duration | Controller effect over days; LABA gives 12-hour bronchodilation. |
| Half-life / level | Local plus systemic components; no routine level. |
| Routes | Inhaled |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | Supportive care. |
| Pregnancy / lactation | Use if needed. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Fluticasone-salmeterol and budesonide-formoterol (brand names Advair, Symbicort) — Asthma and COPD controller; Inhaled corticosteroid plus long-acting beta agonist combination.
Identification
- Therapeutic class: Asthma and COPD controller.
- Pharmacologic class: Inhaled corticosteroid plus long-acting beta agonist combination.
Pharmacology
- Mechanism of action: Combines anti-inflammatory steroid with sustained bronchodilation.
- Onset / peak / duration: Controller effect over days; LABA gives 12-hour bronchodilation.
- Half-life / therapeutic level: Local plus systemic components; no routine level.
Clinical use
- Indications: Asthma and COPD maintenance.
- Usual dose, route, frequency: Inhaled twice daily.
- Maximum dose / adjustments: Per product strength.
Safety
- Contraindications: Acute bronchospasm primary treatment.
- Black box warning: None (the combination format removed the prior LABA boxed warning).
- Interactions: Strong CYP3A4 inhibitors, beta blockers, QT-prolonging drugs.
- Pregnancy / lactation: Use if needed.
- High-alert: No.
Adverse effects
- Common side effects: Thrush, hoarseness, tremor, headache.
- Serious effects to report: Paradoxical bronchospasm, persistent thrush.
- Antidote / reversal: Supportive care.
Nursing process
- Assessment before administration: Respiratory status, oral mucosa.
- Interventions during therapy: Rinse mouth after use; keep a separate rescue inhaler.
- Monitor: Symptom control, heart rate.
- Evaluation / expected outcome: Improved control and fewer flares.
Patient teaching
- Patient teaching: Controller, not a rescue; rinse after use.
- Notify provider if: Increased rescue use, worsening symptoms.
- Administration tips: Twice daily; rinse mouth.